Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Status:
Completed

Trial end date:
2014-07-17

Target enrollment:

Participant gender:

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

Phase 2

Pfizer